Hair analysis and its concordance with self-report for drug users presenting in emergency department.
2016 Oct 01
Journal Article
Authors:
Sharma, G.;
Oden, N.;
VanVeldhuisen, P.C.;
Bogenschutz, M.P.
Secondary:
Drug Alcohol Depend
Volume:
167
Pagination:
149-55
PMID:
27522871
DOI:
10.1016/j.drugalcdep.2016.08.007
Keywords:
Adult; Analgesics, Opioid; Cannabinoids; Cannabis; Cocaine; Drug Users; Emergency Service, Hospital; Female; Hair; Humans; Male; Middle Aged; Reproducibility of Results; Self Report; Substance-Related Disorders
Abstract:
BACKGROUND: Secondary analysis using data from the National Drug Abuse Treatment Clinical Trials Network randomized trial (NCT # 01207791), in which 1285 adult ED patients endorsing moderate to severe problems related to drug use were recruited from 6 US academic hospitals.OBJECTIVE: To investigate the utility of hair analysis in drug use disorder trials with infrequent visits, and its concordance with Timeline Follow Back (TLFB).METHODS: This study compared the self-reported drug use on the TLFB instrument with the biological measure of drug use from hair analysis for four major drug classes (Cannabis, Cocaine, Prescribed Opioids and Street Opioids). Both hair analysis and TLFB were conducted at 3, 6 and 12 month follow-up visit and each covered a 90-day recall period prior to the visit.RESULTS: The concordance between the hair sample results and the TLFB was high for cannabis and street opioids, but was low to moderate for cocaine and prescribed opioids. Under-reporting of drug use given the positive hair sample was always significantly lower for the drug the study participant noted as their primary drug of choice compared with other drugs the participant reported taking, irrespective of whether the drug of choice was cannabis, cocaine, street opioids and prescribed opioids. Over-reporting of drug use given the negative hair sample was always significantly higher for the drug of choice, except for cocaine.CONCLUSIONS: This study extends the literature on hair analysis supporting its use as a secondary outcome measure in clinical trials.
